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Abstract
Triple negative breast cancer (TNBC) is challenging to treat successfully because targeted therapies do not exist. Instead,
systemic therapy is typically restricted to cytotoxic chemotherapy, which fails more often in patients with elevated
circulating cholesterol. Liver x receptors are ligand-dependent transcription factors that are homeostatic regulators of
cholesterol, and are linked to regulation of broad-affinity xenobiotic transporter activity in non-tumor tissues. We show that
LXR ligands confer chemotherapy resistance in TNBC cell lines and xenografts, and that LXRalpha is necessary and
sufficient to mediate this resistance. Furthermore, in TNBC patients who had cancer recurrences, LXRalpha and ligands
were independent markers of poor prognosis and correlated with P-glycoprotein expression. However, in patients who
survived their disease, LXRalpha signaling and P-glycoprotein were decoupled. These data reveal a novel chemotherapy
resistance mechanism in this poor prognosis subtype of breast cancer. We conclude that systemic chemotherapy failure in
some TNBC patients is caused by co-opting the LXRalpha:P-glycoprotein axis, a pathway highly targetable by therapies that
are already used for prevention and treatment of other diseases.
Introduction
Breast cancer (BCa) prognosis depends on tumor and host
parameters. Breast tumors that don’t express the estrogen
(ER), progesterone (PR), and Her2 receptors (ER-/PR-/
Her2-), termed triple negative (TNBC), are challenging to
treat successfully because therapies such as Tamoxifen and
Herceptin that target ER and Her2 signaling, respectively,
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are not effective. Typically, TNBC patients undergo surgical
resection of primary tumor and lymph nodes, radiotherapy,
and systemic cytotoxic chemotherapy. Chemotherapy can be
given either before (neoadjuvant [NACT]) or after (adjuvant
[ACT]) surgery.
NACT is increasingly common to downstage the tumor
to allow breast conserving surgery to be performed [1]. A
clinically measurable surrogate marker of likely outcome
following NACT is pathological complete response (pCR)
to treatment [2]. If pCR is observed after NACT then
prognosis is generally very good and invasive surgery is
minimized. If pCR is not observed then treatment and can
be adapted, but prognosis is worse and patients are likely to
have been better placed on alternative treatments, such as
long term adjuvant chemotherapy after surgical resection
[2]. If TNBC patients are going to relapse with their disease,
they typically do so within 2–3 years [3], highlighting a
substantial subset of patients in whom systemic therapy has
failed and who now have a few remaining treatment
options. Maximizing response to chemotherapy is a critical
clinical need, yet the mechanisms responsible for resistance
remain poorly understood [4].
Circulating cholesterol levels appear to be inversely
linked to survival of BCa patients, and are extensively
modifiable by diet, lifestyle, and pharmacological inter-
ventions. Survival is worse for BCa patients who present
with high LDL-cholesterol [5], but is improved with dietary
[6–8] or pharmaceutical [9] regimens that are associated
with normalized LDL-C. A clinical trial that promoted
dietary methods to reduce LDL-cholesterol was found to
reduce breast cancer recurrence rates [10]. Robust
mechanistic evidence explaining these links remains sparse,
thus the guidance that can be offered to different patient
groups with respect to the potential benefits of reducing
LDL-cholesterol remains limited [11]. Cholesterol is the
precursor for an array of compounds including hormones,
seco-steroids, and bile acids. During the synthesis of these
compounds, a diverse array of oxysterol intermediates are
produced that are potent signaling molecules in their own
right. Hydroxylation of the cholesterol side chain produces
side-chain hydroxycholesterols (scOHC), such as 24-
hydroxycholesterol (24OHC), 26-hydroxycholesterol
(26OHC/27OHC), epoxycholesterols (e.g. 24,25-epox-
ycholesterol), and oxysterol conjugation can produce a
wider variety of signaling molecules such as dendrogenin
A. Oxysterols are continually detected by the liver x
receptor alpha (LXRα) and liver x receptor beta (LXRβ)
transcription factors [12], allowing for homeostatic control
of end product synthesis and simultaneously inhibiting
potentially harmful build-up of oxysterol intermediates [13]
or of cholesterol itself [14]. Selective modulation of LXRα
and LXRβ by oxysterols leads to divergent effects in cancer
pathophysiology. For example, the oxysterol-histamine
conjugate dendrogenin A preferentially activates LXRβ,
induces lethal autophagy [15] and differentiation of breast
cancer cells [16]. Contrary to this, in TNBC scOHCs pro-
mote metastatic colonization [17] and epithelial mesench-
ymal transition, and in ER-positive breast cancers, scOHCs
both reduce endocrine therapy efficacy [18] and are circu-
lating biomarkers of recurrence [19].
Interestingly, there is evidence that LXRα and scOHCs
may also play a role in chemotherapy resistance. LXRα
maintains integrity of the blood brain barrier [20] via
upregulation of the multi-drug resistance pump, P-glyco-
protein, in response to oxysterols [21] and synthetic LXR
ligands [22]. The ATP-Binding Cassette B1 (ABCB1)/P-
glycoprotein (Pgp) is a highly promiscuous xenobiotic
efflux transporter with substrate diversity that includes
cholesterol [23] and an array of chemotherapy agents
typically given to TNBC patients. LXR and Pgp therefore
potentially link oxysterol signaling to chemotherapy effi-
cacy. We previously demonstrated that ER-negative breast
cancer was highly responsive to LXRα signaling compared
to other breast cancer types [24] suggesting retention of the
scOHC:LXR axis provided a survival advantage to TNBC
tumors that persisted despite the anti-proliferative actions
LXR confers. Here, we have explored the hypothesis that
failure of systemic chemotherapy could be attributed to a
cholesterol rich tumor environment, where aberrant activa-
tion of the scOHC:LXR:Pgp signaling axis is co-opted to
confer resistance to common chemotherapy drugs.
Materials and methods
Cell culture and cell lines
Cell lines were originally obtained from ATCC. All cells
were routinely maintained at 37 °C with 5% CO2 in Dul-
becco’s Modified Eagle Medium (DMEM, Thermo Fisher,
Cat: 31966047) supplemented with 10% FCS (Thermo
Fisher, UK, Cat: 11560636). Cell lines were confirmed
mycoplasma free at 6-monthly intervals, and cell line
identities were authenticated at the start of the project.
Drugs and reagents
All stocks were stored at −20 °C. scOHCs were from
Avanti (Alabama, US) and stored as 10 mM stocks in
nitrogen flushed ethanol: 24OHC (#700061), 25OHC
(#700019), 26OHC (#700021). Epirubicin (Cayman, UK
Cat:12091) was stored at 10 mM in nuclease free water and
protected from light. GSK2033 (ToCris, Abindon, UK –
#5694) at 20 mM diluted in ETOH. ABC inhibitors: MK-
571 (Cambridge Bioscience – Cat: 10029–1mg-CAY) and
KO143 (Sigma – Cat: K2144–1mg) were diluted in DMSO,
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while Verapamil (Insight Biotechnology – Cat: sc-3590)
was diluted in NFW; all at 10 mM. TaqMan assays (Thermo
Fisher, Paisley, #4331182): LXRα [Hs00172885_m1]
LXRβ [Hs01027215_g1], Pgp [Hs00184500_m1], ABCA1
[Hs01059137_m1], HPRT1 [Hs02800695_m1]. Origine
trisilencer complexes (Maryland, US): LXRα #SR322981,
LXRβ #SR305039). Antibodies: Pgp (Santa Cruz Biotech,
CA, US - #sc73354), CYP27A1 (Abcam, Cambridge, UK -
#ab126785), CYP46A1 (Abcam, Cambridge, UK -
#ab198889), CH25H (Bioss, MA, US - #bs6480R), LXRα
(R&D System, Minneapolis, US - #PP-PPZ0412-00),
LXRβ (Active Motif, Carslbad, US - #61177). Antibody
validation is described in detail in Supplementary
Information.
Analysis of gene expression
Analysis of gene expression was performed as described
previously [24]. Briefly, mRNA was extracted using
Reliaprep Minipreps for cell cultures (Promega, UK,
#Z6012) and RNA Tissue Miniprep System (Promega,
UK, #Z6112) for tumor samples. GoScriptTM (Promega,
UK, #A5003) was used for the cDNA synthesis. Taqman
Fast Advanced Mastermix (Thermo Fisher, Paisley,
#4444557) was mixed with Taqman assays and analysed in
a 384 well QuantStudio Flex 7 (Applied Biosystems Life
Tech, Thermo Scientific) in 5 μl reaction volumes. siRNA
(30 nM) were transfected with RNAiMAX (Thermo Fisher,
#13778030) according to manufacturer’s instructions with
following adaption. Cells were incubated for 22 h with
reagent/siRNA mixture and then media was exchanged.
After a further 14 h RNA was extracted. All experiments
were conducted in technical triplicate and are presented as
mean ± SEM of three or more independent replicates.
Cell viability assays
MTT
MTT were performed as previously described [24]. Briefly,
2 × 104 cells were seeded in 96 well plates and incubated
overnight. For the combination treatment with EPI, cells
were pre-treated with LXR synthetic ligands (0.1, 0.25, or
1 μM), or scOHC (1, 2.5, or 10 μM) for 24 h. After 24 h
treatment, EPI was added and incubated for the next 48 h.
Cells were washed with 100 μL PBS/well. 90 μL phenol red
free DMEM supplemented with 10% FBS was added to
each well and followed with the addition of 10 μL of diluted
MTT reagent (Sigma-Aldrich, UK, Cat: M2128; final con-
centration 0.5 mg/mL) to each well. After 4 h incubation at
37 °C, media was carefully removed and replaced with
100 μL of DMSO/well. The absorbance was read using a
CLARIOstar plate reader (BMG LABTECH, Germany) at
540 nm. All experiments were conducted with six technical
replicates and are presented as mean ± SEM of three or
more independent replicates.
Colony forming assay
Colony forming assays (CFA) were performed as pre-
viously described [25]. Briefly, cells were suspended to 1 ×
106 cells/mL, 250 μL/well of cell suspension was plated into
6-well plates and topped up to 2 mL with DMEM-10%.
Cells were incubated overnight and then treated with
GW3965, GSK2033, scOHC, or vehicle control (VC)
(ETOH/DMSO/N2F ETOH) for 24 h. Epirubicin (25 nM) or
VC (nuclease free water) was added for a further 24 h. Cells
were then counted and 500 cells per treatment were plated
in triplicate in six well plates (Nunc, Thermo Fisher, UK,
Cat: 10119831) and incubated for 12 days. Colonies were
washed with PBS and stained with a 0.1% crystal violet
staining solution was this in 50% methanol, 30% ethanol,
and 20% ddH20 (Sigma, UK, Cat: V5265-250 ML). Colo-
nies were left to air dry overnight then counted. All
experiments were conducted in technical triplicate and are
presented as mean ± SEM of three or more independent
replicates.
Chemotherapy efflux assay
Cells were plated (50,000 cells/well) in clear bottom black
walled tissue culture 96 well plates (Greiner Bio-One, UK,
Cat: 655986) and pre-treated with either VC (ETOH) or
LXR ligands (GSK2033, GW3965 at 1 µM, 24OHC,
26OHC, 10 µM) for 16 h before exposure to 50 µM epir-
ubicin for 1 h. Cells were gently washed with PBS twice
taking care not to disrupt/detach cells and fresh PBS
(100 µL) was placed in the wells and fluorescence was
measured using a TECAN plate reader at 485 nm excitation
and 590 nm emission. Cells were then placed in the incu-
bator with fresh growth media in the wells and wash steps
and fluorescence read at 15 min intervals for 2 h. Data for
treated wells were normalised to vehicle controls. For pump
inhibitor treatment, drugs were administered to the cells
30 min before epirubicin loading (verapamil − 20 µM,
MK571–50 µM, and KO143–15 µM). All experiments were
conducted in technical triplicate and are presented as mean
± SEM of three or more independent replicates.
In vivo model
All protocols involving mice were approved by the Illinois
Institutional Animal Care and Use Committee at the Uni-
versity of Illinois. Health related concerns were established
as exclusion criteria, but as no mice displayed these
symptoms, all mice were included for analysis. Mouse 4T1
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BCa cells were maintained in DMEM supplemented with
10% calf serum. 1 × 106 cells in a 1:1 ratio of PBS:matrigel
were grafted orthotopic into the axial mammary fat pad of
BALB/c mice at ~11 weeks of age. After engraftment with
4T1 cells, mice were randomized onto treatment. Mice were
split into four groups (ten mice per group was considered an
appropriate number based on previous work) of placebo,
GW3965, epirubicin, or GW3965 and epirubicin combined.
Daily treatment with GW3965 (30 mg/kg) or placebo star-
ted 1 day post-graft. Treatment with epirubicin started
2 days post-graft and was administered every other day at
2.5 mg/kg. Subsequent tumor growth was determined by
direct caliper measurement. At the end of the experiment,
mice were humanely euthanized, and tumors were dissected
and weighed. Personnel measuring tumor volumes were
blinded to treatments groups. Quantification of mRNA was
carried out as described previously [26]. Relative expres-
sion was determined via the 2-ΔΔCT method and normal-
ized to housekeeping gene (TBP).
Human samples: ethical approval, collection, and
processing
A total of 47 fresh/frozen tumor samples for LC-MS/MS and
gene expression analysis were obtained with ethical approval
from the Leeds Breast Research Tissue Bank (15/HY/0025).
Selection criteria were all available ER-negative tumors with
>3 yr follow-up with fresh-frozen tumor material available.
Supplementary Table 1 summarizes the clinic-pathological
features of the “fresh/frozen” cohort. For the tissue micro-array
(TMA) 148 tumor samples were obtained with ethical
approval from Leeds (East) REC (06/Q1206/180, 09/H1306/
108) with informed patient consent. The patient cohort con-
sisted of triple negative/ basal tumors as determined through
immunohistochemistry. Further selection criteria were that
selected tumors had not undergone neoadjuvant therapy,
contained sufficient tumor stroma, had low levels of inflam-
matory cells or necrotic material, and whether normal tissue
was available from archival resection blocks (n= 148). Sui-
table tumor areas were identified through haematoxylin/eosin
stain and 0.6mm cores of tumor tissue removed in triplicate
and deposited into recipient wax block. Supplementary Table
1 summarizes the clinic-pathological features of the TMA
cohort.
Statistics
Analysis of colony forming assays was performed using
paired t tests for comparisons between epirubicin treated
cells with and without pre-treatment with LXR ligands, or
one-way ANOVA after correction for multiple testing when
comparing all treatments at once. Analysis of gene and
protein correlations were assessed using Spearman’s
correlation with linear regression. Significance in gene
expression analyses of genes implicated in chemotherapy
resistance pre- and post-gene silencing and inhibitor loading
was assessed using 2-way ANOVA. The half-life of intra-
cellular epirubicin signal was determined using dissociation
one phase exponential decay and the expression of Pgp in
patient tumors that had suffered an event compared with
those who had not was assessed using Mann–Whitney U
tests. Patient survival was assessed using log rank tests and
in vivo mouse experiments were assessed using one-way
ANOVA and corrected for multiple comparisons.
Supplementary methods are available in the Supplementary
information file where antibody validation (Supplementary
Fig. S1), immunohistochemistry (Supplementary Fig. S2), and
LC-MS/MS (Supplementary Fig. S3) are described.
Results
LXR ligands influence epirubicin response in TNBC
cells in vitro
To establish if the scOHC-LXR axis influences TNBC
chemotherapy response, in vitro assays were used to test
how combinations of epirubicin and LXR ligands altered
tumor cell survival and growth. MTT assays were used as a
readout of cellular health. LXR agonist treatment generally
impaired epirubicin cytotoxicity, while antagonism of LXR
enhanced efficacy. Apply the LXR synthetic agonist
GW3965 increased the concentration of epirubicin needed
to induce cell death (p < 0.0001 for 0.1, 0.25, and 1 μM in
MDA.MB.468 and p < 0.01 for all concentrations in MDA.
MB.231), as did the endogenous agonists 24OHC (p < 0.05)
for all concentrations in both cell lines, and 10 μM 26OHC
(also known as 27-hydroxycholesterol, the product of
CYP27A1; p < 0.05 for both cell lines, Fig. 1A). For all
concentrations of the LXR antagonist GSK2033 tested (Fig.
1B) in MDA.MB.468 cells there was a significant increase
in epirubicin effect (p < 0.0001). In MDA.MB.231 cells
only 250 nM was effective (p < 0.05). Colony forming
assays (CFA) were then conducted with cells pre-treated
with LXR ligands or vehicle control, before being exposed
to epirubicin. As expected, epirubicin treatment alone
(25 nM for 24 h) resulted in a significant attenuation (p <
0.001) of between 40–70 % of the cells’ ability to form
colonies in the following days (note y axis for epirubicin in
Fig. 1C). When LXR agonists GW3965, 24OHC, or
26OHC were combined with epirubicin treatment (Fig. 1C)
we observed significant rescue of colony formation com-
pared to the epirubicin alone (p < 0.01 for all agonists in
both MDA.MB.231 and MDA.MB.468). When the syn-
thetic LXR antagonist GSK2033 was used however (Fig.
1D) the reverse was observed and the efficacy of epirubicin
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was enhanced (p < 0.05). All concentrations of LXR ligands
tested could transactivate LXR [24]. Low doses that had no
effect on proliferation (Supplementary Fig. S4A) or colony
formation (Supplementary Fig. S4B), as well as higher
doses that were antiproliferative in MTT were evaluated to
avoid confounding chemoresistance with anti-proliferative
effects. From these data we concluded that synthetic and
endogenous LXR ligands conferred resistance to epirubicin.
LXRα is linked to Pgp expression and function in
TNBC patients and in vitro
The chemotherapy efflux pump Pgp was a strong candidate
as the mediator of this LXR ligand induced resistance to
epirubicin, as it has previously been reported to be modu-
lated by oxysterols in the blood brain barrier [21]. To
establish if Pgp is potentially regulated by LXRα or LXRβ,
and thus sensitive to cholesterol metabolic flux in the tumor,
we mined publicly available transcriptomics datasets from
TNBC tumors to determine correlation of mRNA expres-
sion, and binding of the LXRs to the Pgp promoter.
Expression of LXRα mRNA was weakly, although sig-
nificantly, correlated with Pgp (Fig. 2A) in both METAB-
RIC (n= 313; p= 0.0024; R= 0.17) and TCGA datasets
(n= 95; p= 0.0076; R= 0.27). No correlations between
LXRβ and Pgp were observed (p > 0.05). Other drug efflux
pumps (MRP1 and BCRP) were not correlated with LXRα
in either dataset (Supplementary Fig. S5A; p > 0.05). As
Fig. 1 LXR ligands induce chemoresistance in triple negative
breast cancer cell lines. MTT assay of epirubicin dose response
following pre-treatment of MDA.MB.468 and MDA.MB.231 cell lines
with low, medium, and high doses of LXR agonists (A) or antagonist
(B). Data shown are mean with SEM of three independent replicates
each performed with six technical replicates. Statistical significance
was determined using non-linear regression curve comparison against
epirubicin (EPI) only curve. Colony Forming Assays measuring how
the ability of MDA.MB.468 and MDA.MB.231 cell lines to generate
colonies after epirubicin exposure is improved by pre-treating cells
with LXR agonists (C) or antagonist (D). Three or four independent
replicates were performed (as indicated), each independent replicate is
the mean of three technical repeats. p values were calculated using
paired t test.
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LXR is autoregulated, and we expected LXR mRNA levels
to associate with its transcriptional output, we hypothesized
that expression of canonical LXR target genes should
correlate with expression of the novel target gene, Pgp.
Indeed, we found ABCA1 to significantly positively cor-
relate with Pgp in both METABRIC and TCGA datasets
Fig. 2 Pgp expression and function is linked to LXR activity. A
Correlation analysis in TNBC tumors of LXRα or LXRβ with ABCA1
and Pgp gene expression obtained from METABRIC (n= 313) and
TCGA (n= 95) datasets accessed via cBioportal. Statistical sig-
nificance was assessed using Pearson’s correlation test with linear
regression. B–G performed in MDA.MB.468 cells except where
indicated. Pgp expression measured at 4 h and 16 h after ligand
exposure at mRNA level (B) and after 24 h for protein analysis (C). D
siRNA knockdown of LXRα or LXRβ. B–F Symbols show inde-
pendent replicates and bars show mean with SEM. Statistical analysis
was performed using 2-way ANOVA and is representative of three
independent replicates with SEM. (E) Colony forming assay in MDA.
MB.468 cells after siLXRα showing GW3965 (GW) no longer
protects cells from epirubicin in the absence of LXRα. (F) MTT in
MDA.MB.468 cells after siPGP shows GW no longer protects cells
from epirubicin in the absence of Pgp. (G) MDA.MB.468 and MDA.
MB.231 cells were pre-treated with LXR ligands or vehicle for 16 h
and Pgp inhibitor (verapamil 20 μM [V20]) or vehicle for 30 min,
before loading with epirubicin (50 μM) for 1 h. The half-life of the
intra-cellular epirubicin signal was calculated using dissociation one
phase exponential decay. NB: epirubicin curve data are replicated in
each graph for visualization purposes. Data shown are mean with SEM
of three or four independent replicates each made from six technical
replicates. Significance was calculated using non-linear regression
curve comparison against epirubicin (EPI) only curve.
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(Supplementary Fig. S5B; p < 0.0001 for both). We next
investigated if LXRα or LXRβ could directly bind the Pgp
promoter using mouse macrophage and liver tissue datasets,
available in the cistrome.org ChIP-Seq repository. LXRα
but not LXRβ, accumulated in the promoter region of Pgp
in response to treatment with LXR agonist (Supplementary
Fig. S6). As a positive control, we also confirmed that both
LXRα and LXRβ accumulated in the promoters of known
LXR target genes ABCA1 and APOE (Supplementary Fig.
S6). These data are consistent with the hypothesis that
LXRα, but not LXRβ, is able to bind the Pgp promoter
region. Furthermore, expression of LXRα, but not LXRβ, is
positively correlated with Pgp expression in the tumors of
TNBC patients in separate publicly available datasets.
To ascertain if Pgp was regulatable by LXR ligands in
TNBC cells, we treated MDA.MB.468 cells with a range of
LXR ligands and found significant up- and down-regulation
of Pgp mRNA in response to agonists or antagonists,
respectively, at two different time-points (Fig. 2B). Induc-
tion of Pgp by GW3665 at protein level was confirmed in
MDA.MB.468 and MDA.MB.231 cells (Fig. 2C). To test
which LXR isoform was primarily responsible for Pgp
induction, siRNA was used to knock down LXRα and
LXRβ separately. siLXRα significantly diminished Pgp
expression (Fig. 2D; p < 0.01), demonstrating that LXRα
positively regulates Pgp, and also halted the agonist
GW3965’s ability to protect cells from epirubicin in CFA
(Fig. 2E; p > 0.05), demonstrating the functional impact of
LXRα’s control of Pgp. Knock-down of LXRβ did not
reduce Pgp expression. Furthermore, siPgp ablated the
ability of GW3965 to confer protection from epirubicin
(Fig. 2F). siLXRα and siLXRβ knockdown efficiency was
confirmed at protein (Supplementary Fig. S7A) and mRNA
levels (Supplementary Fig. S7B), as was loss of expression
of canonical target gene expression (Supplementary Fig.
S7B). Knock down of either LXR isoform had no effect on
expression of MRP1 (Supplementary Fig. S7C; p < 0.05) or
BCRP efflux pumps (Supplementary Fig. S7D; p < 0.05).
After establishing Pgp expression was at least in part
dependent on the scOHC-LXRα axis, and that this signaling
pathway protected TNBC cells from chemotherapy, we
hypothesized that Pgp’s drug efflux function was crucial.
We developed a novel chemotherapy efflux assay allowing
time-resolved monitoring of intracellular epirubicin con-
centration in a high throughput system by exploiting epir-
ubicin’s natural fluorescence. After pre-treating MDA.
MB.468 or MDA.MB.231 cells with vehicle control (VC;
ethanol), LXR agonist (GW3965, 24OHC, or 26OHC), or
antagonist (GSK2033) cells were then ‘loaded’ with epir-
ubicin and intra-cellular epirubicin measured at 15 min
intervals as the epirubicin was pumped out. The half-life
(t½) of epirubicin signal in vehicle treated control cells was
13.05 min for MDA.MB.468 cells and 16 min for MDA.
MB.231 (Fig. 2E) and all pre-treatments were compared
back to this vehicle/epirubicin condition with one-phase
decay non-linear regression model. GW3965 pre-treatment
led to a significant reduction in epirubicin retention time to
t½= 10.98 min (p= 0.00899) and t½= 12.28 min (p <
0.0001) in MDA.MB.468 and MDA.MB.231 cells,
respectively, (note shift of Epi curve [open circles with solid
line] to left with addition of GW3065 [open squares with
dotted line]). scOHC pre-treatment also significantly (p <
0.0001 for all) shifted curves to the left, again indicating
decreased epirubicin retention time (468 cells: 24OHC t½=
8.27 min, 26OHC t½= 9.62 min; 231 cells: 24OHC t½=
12.28 min, 26OHC t½= 12.38 min). This enhanced efflux
of epirubicin was reversable by the Pgp specific inhibitor
verapamil (V20) (note shift of curve to the right with V20 as
denoted by closed squares), demonstrating the dependence
on Pgp function. In contrast, inhibiting LXR activity with
the synthetic antagonist GSK2033 led to significantly
increased retention of epirubicin (468 cells: t½= 20.19 min;
231 cells: 231 cells t½= 25.86 min p= 0.0004), and this
was not reversed or enhanced by verapamil (p > 0.05).
Overall intra-cellular epirubicin accumulation was also
lower in LXR agonist treated cells (Supplementary Fig.
S8A). Experiments with selective inhibitors demonstrated
that Pgp but not other drug efflux pumps (MRP1, BCRP)
was necessary and sufficient for LXR mediated epirubicin
efflux in control experiments (Supplementary Fig. S8B, C).
LXR activation confers chemoresistance and
enhances Pgp expression in vivo
To corroborate in vivo these chemoprotective effects of the
scOHC-LXR axis, a preclinical model using TNBC syn-
geneic 4T1 cells grafted in mammary fat pads of Balb/c
mice was evaluated. Mice in four groups were treated with
either vehicle control, GW3965, epirubicin, or GW3965
and epirubicin combined. As expected, epirubicin reduced
tumor growth (Fig. 3A) and final size (Fig. 3B), as did
GW3965. The tumors of mice in the combination group
grew significantly more quickly (p < 0.0001) and were
significantly larger (p < 0.0001) than the epirubicin alone
group. Analysis of resected tumors indicated significantly
increased expression of both canonical Abca1 (p < 0.001)
and Abcb1b (the mouse gene for Pgp) (p < 0.0001) in
GW3965 treated animals compared to controls (Fig. 3B),
demonstrating that the LXR agonist had effectively acti-
vated relevant target genes within the tumor tissue. Mice in
all groups gained weight at a similar rate through the
experiment (p > 0.05) indicating mouse health was similar
between groups over the experimental period (Supplemen-
tary Fig. S9A). Other drug efflux pumps were not found to
induced by GW3965 in this model (Supplementary Fig.
S9B). We concluded that activation of LXR in vivo induced
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expression of Pgp and confers chemoresistance as observed
in vitro.
LXR and its ligand regulators are correlated with
Pgp and are prognostic indicators in ER-negative
BCa patients
To investigate if LXRα protein was associated with Pgp
expression in ER-negative breast cancer patients, ABCA1
mRNA, Pgp mRNA, LXRα protein expression were
measured in a cohort of ER-negative tumor samples from
the Leeds Breast Research Tissue Bank (LBRTB cohort:
n= 47; patient characteristics reported in Supplementary
Table S1; representative immunoblots shown in Supple-
mentary Figure S10). LXRα protein was positively cor-
related with mRNA expression of Pgp (Fig. 4A; p=
0.0046; r= 0.43), validating previous mRNA analyses
from public datasets (Fig. 2A). Kaplan–Meier survival
analyses after the cohort was dichotomized into low and
high expression groups for LXRα indicated that high
LXRα (Fig. 4B; p= 0.0051) were associated with sig-
nificantly worse prognosis.
To explore if Pgp protein expression and patient prog-
nosis were associated with synthesis of OHC, we undertook
two analyses. First, a large-scale analysis of scOHC syn-
thesizing enzyme expression in TNBC tumors in a micro-
array of formalin fixed tissue (TMA cohort: n= 148; patient
characteristics reported in Supplementary Table 1). Pgp
protein expression in TNBC epithelial cells was a strong
indicator or shorter disease-free survival (Fig. 4C; p=
0.004), and expression was strongly and significantly
positively correlated with protein expression CYP46A1
(p < 0.0001; R2= 0.3) and CH25H (p < 0.0001; R2= 0.57),
and weakly with CYP27A1 (p= 0.004; R2= 0.07) (Fig. 4D
– left panels), enzymes that synthesize 24OHC, 25OHC,
and 26OHC, respectively.
Shorter disease-free survival was found in patients
with high expression of CYP46A1 (p= 0.005) and
CH25H (p= 0.0072), but not CYP27A1 (p > 0.05)
(Fig. 4D – right panels). Second, a smaller analysis was
performed in the LBRTB cohort where fresh-frozen tissue
was available thus allowing direct LC-MS/MS measure-
ments of scOHC concentrations in matched tumor sam-
ples to protein lysates measured in Fig. 4D. 24OHC (but
not 25OHC or 26OHC) metabolite concentrations were
significantly positively correlated with Pgp mRNA
expression (Fig. 4E – left panels); high concentration of
all three metabolites (24OHC p= 0.026; 25OHC p=
0.011; 26OHC p= 0.01) were prognostic of shorter
disease-free survival (Fig. 4E – right panels). From these
data we concluded that multiple components of the LXR
signaling pathway were likely to converge on Pgp
mediated drug resistance and contribute to shorter
disease-free survival in TNBC patients.
Fig. 3 LXR activation drives
Pgp expression and
chemotherapy resistance
in vivo. 4T1 cells (TNBC) were
grafted orthotopically into the
axial mammary fat pad of
BALB/C mice. Mice were
treated with either placebo or the
LXR ligand GW3965 (daily,
30 mg/kg) 24 h post-graft.
Treatments with placebo or
epirubicin (every other day,
2.5 mg/kg) commenced 48 h
post-graft. Tumor volumes
measured by calipers (A) or
tumor weight (mg) after 12 days
(B). Statistical analysis was
assessed using non-linear
regression. C Expression of
Abca1, and Pgp was assessed by
qPCR analysis. Statistical
analysis was assessed using one
way ANOVA with SNK test,
with 10 mice per group
(individual symbols) and shown
with median and range.
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LXRα and its ligands are decoupled from Pgp in
surviving TNBC patients, but remain linked in
patients who suffer relapse or die
After establishing a mechanism linking the cholesterol
metabolic sensor, LXRα, with chemotherapy resistance at
the molecular level, and discovering a discernable effect on
survival in cell lines, pre-clinical models and patients, we
wanted to explore if measuring activity of the scOHC:LXR
pathway could separate surviving patients from those who
relapse or died from their disease. We split the LBRTB
cohort (Supplementary Table 1) into a “no event” group,
Fig. 4 LXRα protein expression is correlated with Pgp expression
and is a molecular marker of poor prognosis in ER-negative breast
cancer patients. A Correlation analysis between LXR protein
expression and matched mRNA of Pgp in 47 ER-negative breast
tumors (relative to HPRT). Line indicates linear regression, correla-
tions calculated using Pearson correlation. Kaplan–Meier survival
plots following stratification of the cohort into high and low LXRα (B)
and Pgp (C) expression. Log-rank tests used to calculate significance.
D Tissue microarray of 148 TNBC tumors stained for indicated pro-
teins determined by immunohistochemistry and correlated with Pgp
protein (left) and disease-free survival (right). E scOHC concentrations
determined by LC-MS/MS and correlated with Pgp protein (left) and
disease-free survival (right). Correlations calculated with Pearson’s
test and survival differences with log-rank test and Kaplan–Meier
curves.
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i.e., those who did not have a recurrence during follow up
(median follow up time= 96 months), and an “event”
group, i.e., those who had either died from their disease or
had relapsed (median time to event= 20 months). Protein
expression of LXRα (p= 0.076), and mRNA expression of
ABCA1 (p= 0.0121) and Pgp (p= 0.0015) were higher in
the “event” group (Fig. 5A) indicating greater activity of the
LXR signaling axis in the event group; interestingly, the
concentrations of scOHC metabolites were not significantly
different between the event and no event groups (Supple-
mentary Fig. S11). We also tested the correlations between
expression of Pgp and its regulators LXRα and 24OHC in
the cohort, separating patients who had an event from those
who didn’t; LXRα protein was only correlated with Pgp in
the event group (Fig. 5B; p= 0.0012) and similarly,
24OHC was only correlated with Pgp in the event group
(Fig. 5C; p= 0.01). We tested this relationship in the
METABRIC cohort and found that LXRα only correlated
with Pgp in patients who had died from their disease or who
had relapsed (Supplementary Fig. S12; p= 0.017).
Discussion
The purpose of this study was to evaluate the role of cho-
lesterol side-chain hydroxylation products on chemotherapy
resistance, specifically in TNBCs—the breast cancer sub-
type in which chemoresistance is most problematic. We
demonstrated that LXRα activation is linked to che-
motherapy resistance in vitro and in vivo, and to worse
patient survival. We conclude that this is due, at least in
part, to the chemotherapy efflux pump Pgp being a tran-
scriptional target of the scOHC:LXR axis, thus linking
cholesterol status with the innate ability of a triple negative
tumor cells to evade chemotherapy. A major observation
from our data was that patients stratified by survival status
had divergent LXR signaling pathways; the tumors of the
patients who died were enriched for scOHC synthesizing
enzymes and the metabolite 24OHC, and there was a
positive correlation between Pgp and individual compo-
nents of the signaling axis. In patients who did not have
recurrences, these signaling components were not correlated
with Pgp, irrespective of which cohort we evaluated, indi-
cating that actual decoupling of LXR from Pgp in these
tumors was contributing to survival.
The role of drug efflux pumps such as Pgp, BCRP, and
MRP1 in TNBC resistance have been described [27, 28].
Yet directly targeting these pumps has largely failed as a
clinical strategy due to the essential roles that xenobiotic
efflux pumps play in healthy tissue, from side effects from
drug–drug interactions, and lack of specificity [29]. The
factors that determine whether pCR is achieved are impor-
tant to elucidate because patients for whom only a partial
pathological response with NACT is achieved typically do
worse than those who elect for ACT [2]. Cancer specific
mechanisms of efflux pump regulation have been identified,
but until now have largely been attributed to oncogenic
signaling pathways converging on their transcriptional
regulation [28, 30]. The data reported here however indicate
a new direction; we provide evidence of a direct link
between the expression and function of Pgp, and metabolic
flux of cholesterol, a nutrient that is modifiable by diet,
lifestyle, and existing pharmacological approaches. In this
context, the findings presented here lead to speculation that
two clinical hypotheses are appropriate for further evalua-
tion. First, patients stratified based on LXR activity may be
predicted to achieve different rates of pCR after NACT, or
survival after ACT. Second, a therapeutic adjunct that limits
Fig. 5 LXR is decoupled from
Pgp in the tumors of patients
who survive. A Protein
expression (LXRα), and mRNA
expression for ABCA1 and Pgp
were assessed using one-tailed
Mann–Whitney test in the
LBRTB cohort comparing event
and no event groups. Pearson
correlation analysis between
matched Pgp mRNA and either
immunoblotting for LXRα
protein (B), LC-MS/MS for
24OHC (C).
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scOHC synthesis may improve pCR rates. Cholesterol
lowering approaches are already in clinical practice for the
management of cholesterol related diseases. Excitingly,
these interventions could be tailored to the patient to offer
an element of control to individuals who may otherwise
seek lifestyle an dietary guidance from sources that have not
been peer reviewed [31]. It of course remains to be deter-
mined if such strategies would be beneficial in improving
survival rates via chemosensitization, but it is encouraging
that extra-hepatic scOHC levels are modifiable by diet
[32, 33] as well as circulating levels being highly responsive
to statins [34]. A meta-analysis of statin use in unstratified
breast cancer patients has shown inhibition of cholesterol
synthesis was associated with protection from relapse and
death in the first 4 years post-diagnosis [35], which inter-
estingly, is the period of highest relapse risk for TNBC
patients [3].
LXR ligands are being explored in clinical trials as novel
therapeutics, and as diagnostic and prognostic tools. Within
these studies, important distinctions between activation of
LXRα and LXRβ need consideration. The histamine con-
jugated oxysterol such as dendrogenin A, preferentially
activates LXRβ and drives lethal autophagy [15] and dif-
ferentiation of breast cancer cells [16], and synthetic the
LXRβ agonist RGX-104 enhances cytotoxic T lymphocyte
tumor destruction [36]. Dual LXRα/LXRβ ligands such as
26OHC convincingly slow tumor growth through the anti-
proliferative activities of LXR, yet drive LXR dependent
metastasis [37] and substitute for estrogen to drive ER
dependent breast cancer growth [37, 38]. Furthermore, cir-
culating dual LXR oxysterol ligands may be prognostic and
therapeutic indicators [19]. Our data do not indicate the Pgp
expression is the sole cause of LXRα mediated che-
motherapy resistance. Pgp induction and repression by LXR
ligands, and knock-down expression was modest, with
between around 1.5-fold changes being observed. This
would suggest that LXRα may be able to influence a wider
repertoire of chemotherapy resistance mechanisms. Non-
cancer cell sources of endogenous LXR ligands are fre-
quently found in the tumor microenvironment. Macro-
phages, adipocytes, and fibroblasts are all highly efficient at
producing hydroxycholesterols and their presence in the
tumor microenvironment are also markers of outcome in
several cancer types.
Mechanisms that lead to innate chemoresistance have
previously been flagged as a critical research gap [4]. LXR
is a sensor and homeostatic regulator of nutritional status, so
our data support the hypothesis that a cholesterol rich
environment during tumor development may actually con-
tribute to innate chemoresistance, thus addressing a critical
research gap. Ligand dependent activation of LXR in many
tissues is controlled by factors that can be influenced by the
diet and existing pharmacological agents, making this
pathway attractive for therapeutic targeting. Our results
suggest efficacy of cytotoxic therapies may be reduced if
LXRα is stimulated; caution should be applied in clinical
application of dual LXR ligands or of LXRα agonists, as
novel cancer therapeutics. Encouragingly, further clinical
investigation where dietary advice or statins that acutely
lower circulating or tissue scOHC levels could evaluate
LXR modulation to improve pCR rates in this hard to cure
subgroup of breast cancer patients. In conclusion, endo-
genous synthesis of LXR ligands and LXRα activity are
prognostic indicators for TNBC patient survival and should
be explored prospectively in the clinical setting as func-
tional and targetable prognostic indicators for response to
chemotherapy.
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